| Old Articles: <Older 4791-4800 Newer> |
|---|
 |
Chemistry World
April 24, 2008
James Mitchell Crow |
FDA takes tough line on biologic drug The US Food and Drug Administration has rejected an application from biotechnology firm Genzyme to make its already-approved, protein-based drug Myozyme in larger batches.   |
The Motley Fool
April 24, 2008
Brian Lawler |
FDA Stings Genzyme Earnings A nasty surprise hurts the drug developer's first quarter results. |
The Motley Fool
April 24, 2008
Brian Orelli |
Is Schering-Plough the Comeback Kid? Schering posts an OK quarter despite the slowdown in sales of its cholesterol drugs. |
The Motley Fool
April 24, 2008
Brian Orelli |
Illumina Ignites This biochip maker is on fire. |
The Motley Fool
April 24, 2008
Rich Duprey |
Candela Fizzles Aesthetic laser maker Candela reports slightly higher revenue but wider-than-anticipated losses. |
The Motley Fool
April 23, 2008
Brian Lawler |
Vertex Verging on Crucial News Soon-to-arrive study results could decide the future of Vertex Pharmaceutical's lead drug telaprevir. |
The Motley Fool
April 23, 2008
Brian Orelli |
Wyeth Recovers From Its Heartburn Wyeth deals with generic competition for one of its biggest drugs. |
The Motley Fool
April 23, 2008
Brian Lawler |
Glaxo's Three-Quarter-Billion-Dollar Gamble Glaxo adds another development stage drugmaker to its portfolio. Investors take note. |
The Motley Fool
April 23, 2008
Brian Orelli |
Boston Scientific Gets It Done After a rough 2007, it looks like Boston Scientific is turning itself around from the bottom up. |
The Motley Fool
April 22, 2008
Brian Orelli |
Will Merck Make It? Merck releases first-quarter results and says it can meet its previous guidance. |
| <Older 4791-4800 Newer> Return to current articles. |
